---
title: "Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes"
id: "clinicaltrials-nct05819138"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct05819138"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT05819138"
doi: "NCT05819138"
published_at: "2026-03-04T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct05819138
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT05819138)
- **DOI:** [NCT05819138](https://doi.org/NCT05819138)
- **Published At:** 2026-03-04T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
RECRUITING · INTERVENTIONAL · TREATMENT study · Diabetes Mellitus, Type 1 · Phase 3 · Enrollment 60 · Sponsor: University of Colorado, Denver
## Clinical Analysis & Structured Key Points
Official title: Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes Summary: This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental. Conditions: Diabetes Mellitus, Type 1 Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE3 Enrollment: 60 (ESTIMATED) Status: RECRUITING Completion: 2027-12-01 (ESTIMATED)
## Related Clinical Research

- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Insulin promotes RAGE ectodomain shedding via AKT‑ and Rab14‑dependent ADAM10 trafficking in HAECs](https://medichelpline.com/clinical-feed/plos-one-22-insulin-enhances-rage-ectodomain-shedding-by-inducing-rab14-dependent-adam10.md)
- [Endocrine Society Roadmap: Research Priorities and Gaps in Obesity Science](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-scientific-statement-provides-research-roadmap-for-what-s.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.